Ambulatory Heart Failure GDMT

Scope: stable ambulatory HF—not shock or acute decompensation. In HFrEF, start the four foundational classes early and reach the maximally tolerated regimen, ideally within 3 months. Recent ED/HF hospitalization raises outpatient risk and warrants a tighter early cadence; rapid optimization with close follow-up reduced 180-day death/HF readmission from 23.3% to 15.2% in STRONG-HF. Every visit ends with a change, lab date, follow-up date, and named owner.

Confirm the treatment lane

EF + trajectory change the plan

Phenotype	Core move	Pharmacy implication
HFrEF · LVEF ≤ 40%	ARNI + evidence-based BB + MRA + SGLT2i	Find every missing pillar and every subtarget dose. A low dose of all four usually has more value than maximizing one while leaving gaps.
HFimpEF	Continue HFrEF therapy	Normalized EF is not permission to deprescribe. Withdrawal caused frequent relapse in TRED-HF.
HFmrEF / HFpEF · LVEF > 40%	SGLT2i + finerenone eGFR ≥60: 20→40 mg qd eGFR 25–59: 10→20 mg qd	Option: finerenone (FDA indication LVEF ≥40%) when baseline K⁺ ≤5.0 and access allow; check K⁺/eGFR at 4 weeks. Spironolactone may be considered in selected higher-EF patients. Eplerenone is not an evidence-equivalent substitute in HFpEF—choose one MRA, never stack. Evidence qualifier: TOPCAT directly tested spironolactone; eplerenone has HFrEF evidence, without equivalent HFpEF outcome evidence. Dapagliflozin and empagliflozin are clinical peers. Avoid BB solely for HFpEF; reserve for AF/rate, ischemia, prior MI, or another indication.

The eight-step pharmacist encounter

repeat until optimized

1Reconcile

What is prescribed, filled, taken, skipped, split, or stopped? Include OTCs, supplements, salt substitutes, and prior intolerances.

2Phenotype + cause

LVEF/date/trajectory, NYHA, rhythm, QRS/LBBB, ischemic vs nonischemic vs tachyarrhythmia cause, CKD/DM, and recent HF event.

3Stability

Congestion vs euvolemia; perfusion; orthostasis; current infection, poor intake, AKI, surgery, or pregnancy risk.

4Measure

BP seated/standing, HR/rhythm, weight/volume, K⁺, SCr/eGFR, Na⁺, Mg²⁺, loop response, and BNP/NT-proBNP trend.

5Map gaps

Four classes present? Evidence-based BB? ARNI preferred? Target or maximally tolerated dose? Document the reason for each gap.

6Choose

Start missing low-BP-effect pillars first when needed; then increase one or more doses using the physiologic constraints below.

7Make it doable

Resolve cost/refill/complexity barriers. Favor whole-tablet strengths; do not assume the patient will split pills.

8Close loop

Exact dose/date, hold rules, lab order/date, next contact, patient teach-back, prescriber communication, and escalation owner.

Let physiology choose the next move

order is flexible · safety is not

Current constraint	Usually easiest to add / preserve	Pause, correct, or review first
Low BP · stable	SGLT2i and MRA usually have little BP effect; keep low doses across classes when possible.	Confirm symptoms/orthostasis; remove non-HF vasodilators; reduce loop if euvolemic. ARNI is usually the strongest BP-lowering pillar; stagger or downshift it if needed.
Bradycardia / AV disease	ARNI, MRA, SGLT2i	Review digoxin, amiodarone, diltiazem/verapamil, and conduction disease before increasing BB.
Hyperkalemia risk	BB, SGLT2i; ARNI may be retained with close monitoring.	Stop K⁺ supplements/salt substitutes and NSAIDs; review MRA/RAASi dose and consider a K⁺ binder.
Congested · stable	MRA + SGLT2i are congestion-friendly; use a loop for residual clinical volume.	Do not increase BB until congestion improves. Once euvolemic, work toward the lowest effective loop dose or off with a monitoring plan.
Stable · BP/HR/K allow	Start missing classes now; increase toward target every 1–2 weeks.	Do not wait for one drug to reach target before adding the next class.

When a pillar counts as implemented

prescribed is not the endpoint

Correct therapy	Meaningful intensity	Safe feedback loop	Sustainable execution
Right class and agent; the patient is actually taking it. No duplicate RAAS/MRA or obsolete list entry.	Target or maximally tolerated; an objective limiter and revisit plan are documented for every subtarget dose.	Current vitals/labs; next lab/contact is booked and a named clinician owns the result and next change.	Affordable and in hand; the patient can teach back dose, purpose, hold rules, refill route, and escalation plan.
Not yet implemented: “recommended,” prescription pending, unaffordable at the pharmacy, patient unsure how to take it, safety lab not ordered, or “intolerant” without the symptom/mechanism and attempted workaround.

SCOPE

Exit routine ambulatory titration and contact the prescriber/HF team for hypoperfusion, new/worsening congestion, symptomatic hypotension or bradycardia, high-grade AV block, rapidly rising K⁺/SCr, angioedema, suspected ketoacidosis, pregnancy, or an unclear indication/diagnosis. Pair this guide with the discharge GDMT chapter only for a recent hospital-to-clinic transition.

HFrEF RAAS therapy: ARNI when feasible. When ARNI is not feasible, use an ACE inhibitor or ARB as appropriate for tolerance, indication and access. An ARB is useful when ACE inhibitor cough limits therapy. Use only carvedilol, metoprolol succinate, or bisoprolol as the HFrEF beta-blocker; titrate BB by HR/rhythm. Treat MRA and SGLT2i as congestion-friendly pillars and reassess the loop dose as they take effect.

1ARNI · ACEi/ARB alternatives

PreferredSacubitril/valsartan 49/51 mg BID → 97/103 mg BID; use 24/26 mg BID with no/low prior ACEi/ARB, eGFR <30, or Child-Pugh B.

BP leverUsually the most BP-lowering pillar. Choose dose by BP/symptoms; pursue target when tolerated, but keep a tolerated lower dose rather than stop it.

Hard stops36-hour ACEi washout; never combine ARNI with ACEi/ARB. Avoid with prior ACEi/ARB-related angioedema and in pregnancy.

MonitorBP/orthostasis, K⁺, SCr/eGFR about 1–2 weeks after start/dose change; assess cough, dizziness, volume status.

Counsel“This protects the heart even when you feel well.” Report facial/tongue swelling urgently. NT-proBNP is less directly affected by neprilysin inhibition. Interpret either peptide with the same assay, timing and clinical context.

FallbacksACEi or ARB when ARNI is not feasible. Choose by indication and tolerance. Relative ARNI benefit vs enalapril persisted after dose reduction in PARADIGM-HF; that does not prove no dose-response, so re-attempt target if tolerance improves.

2Evidence-based beta-blocker

Carvedilol3.125 mg BID → 25 mg BID (<85 kg) or 50 mg BID (≥85 kg)

Metoprolol XL12.5–25 mg daily → 200 mg daily

Bisoprolol1.25 mg daily → 10 mg daily

Start whenStable and euvolemic; not acutely decompensated; no symptomatic bradycardia or high-grade block.

TitrateHR/rhythm is the functional target. In sinus HFrEF, increase about every 2 weeks toward trial dose or a documented maximum; BP matters when symptomatic.

MonitorHR/rhythm, BP/orthostasis, weight, fatigue, dizziness, congestion. Do not abruptly stop an established BB without a clinical reason.

3Mineralocorticoid receptor antagonist

Eplerenone25 mg daily → 50 mg daily

Spironolactone12.5–25 mg daily → 25–50 mg daily

Start whenK⁺ < 5.0 mmol/L and eGFR > 30 mL/min/1.73 m²; confirm no duplicate MRA/K⁺ supplement.

MonitorK⁺/SCr within 3–7 days, again near 4 weeks, after each dose/clinical change, then periodically.

PracticeConsider eplerenone when endocrine adverse effects are a concern to avoid spironolactone gynecomastia/sexual adverse effects. Favor whole tablets; if 12.5 mg spironolactone requires splitting, use a feasible whole-tablet alternative when appropriate.

PreserveFor recurrent hyperkalemia, remove contributors and consider a binder rather than reflexively abandoning RAASi/MRA; DIAMOND supports K⁺ control and better MRA persistence.

4SGLT2 inhibitor

Dapagliflozin10 mg daily · no titration

Empagliflozin10 mg daily · no titration

ChoiceJardiance and Farxiga are clinical peers; choose by formulary and cost. Generic dapagliflozin often wins on access.

Avoid / pauseDo not use routinely in type 1 diabetes; individualize after prior DKA. Hold ≥3 days before major surgery/prolonged fasting and during acute illness with poor intake; restart only when clinically stable and eating.

VolumeReassess loop need after initiation. Do not automatically reduce it in residual congestion; if euvolemic/dry, work toward the lowest effective dose or an off-trial with weight/symptom surveillance.

CounselGenital hygiene; hydrate to plan; seek care for nausea, abdominal pain, dyspnea, or malaise because DKA can occur with near-normal glucose.

Not routineBexagliflozin has only a T2DM glycemic indication—not an HF indication; no routine role when a proven HF agent is obtainable.

✓

Before the first dose

four checks prevent most avoidable harm

Medication history	Physiology	Laboratory	Execution
ACEi timing · angioedema · BB identity · duplicate RAAS/MRA · OTC NSAID/K⁺ · pregnancy risk	Congestion · perfusion · seated/standing BP · HR/rhythm · oral intake · diuretic need	K⁺ · SCr/eGFR · Na⁺ · Mg²⁺; recent trend matters more than one isolated value	Coverage/cost confirmed · prescription in hand · counseling/hold rules · lab and follow-up already booked

↺

Build the outpatient prescription bundle

the order is more than the drug

Medication order	Safety orders	Patient plan	Access & ownership
Drug, whole-tablet strength when feasible, exact sig, start date, quantity/refills; explicitly discontinue the replaced/duplicate order.	Baseline BP/HR/K⁺/SCr; lab order and due date; drug-specific hold rules; named result reviewer.	Plain-language schedule and purpose; sick-day/procedure instructions; side-effect and escalation plan; teach-back.	Formulary/cost/stock checked; pickup/delivery confirmed; refill due date; next contact and titration owner.
Switch cleanly: ACEi → ARNI requires a documented 36-hour gap; ARB → ARNI has no washout but must not overlap; discontinue the old formulation when changing BB or MRA; when adding SGLT2i, reassess volume and whether the loop dose needs adjustment.

VERIFY

Doses above are guideline targets, not mandates. The endpoint is the target dose or the documented maximally tolerated dose. Verify current labeling, renal thresholds, formulary rules, and the collaborative practice agreement before prescribing or titrating.

“Renal dosing” is not one class rule. Use the agent-specific boundary, the clinical trajectory, and the exact indication. Distinguish trial enrollment limits, label initiation thresholds, and a true contraindication; then document the hold and restart criteria rather than leaving therapy off indefinitely.

Agent-specific kidney and interaction boundaries

current U.S. labeling · verify updates

Agent	Start / renal boundary	Hard interaction or monitoring rule
Sacubitril/valsartan	Usual 49/51 mg BID; start 24/26 mg BID with no/low prior ACEi/ARB, eGFR <30, or Child-Pugh B; double every 2–4 weeks as tolerated.	36-hour ACEi gap; no ACEi/ARB overlap; avoid prior ACEi/ARB angioedema and pregnancy. K⁺ drugs, NSAIDs, lithium, renal-artery stenosis, and volume depletion require deliberate review.
Eplerenone / spironolactone	HFrEF guideline gate: eGFR >30 and K⁺ <5.0. Eplerenone label: 25→50 mg qd; check K⁺ baseline, within 1 week, at 1 month, then periodically.	Eplerenone: CrCl ≤30 and strong CYP3A inhibitors are contraindications; with a moderate CYP3A inhibitor, post-MI HFrEF dose should not exceed 25 mg qd. Review TMP-SMX, NSAIDs, K⁺/salt substitutes, ACEi/ARB/ARNI.
Finerenone · LVEF ≥40%	Baseline K⁺ ≤5.0. eGFR ≥60: 20→40 mg qd; eGFR 25–59: 10→20 mg qd; do not initiate eGFR <25. Recheck K⁺/eGFR at 4 weeks.	Strong CYP3A inhibitors and adrenal insufficiency are contraindications; avoid grapefruit and strong/moderate inducers. Moderate/weak inhibitors or K⁺-raising drugs require closer K⁺ surveillance. Use one MRA only.
Dapagliflozin	10 mg qd. For HF/CKD, label permits initiation at eGFR ≥25; if eGFR later falls below 25, therapy may continue for cardiorenal benefit.	Assess renal function and volume first. Hold ≥3 days before major surgery/prolonged fasting; resume only when clinically stable and oral intake has resumed.
Empagliflozin	10 mg qd. HF trials enrolled eGFR ≥20; label notes no HF/CKD trial enrollment below 20 or on dialysis—route initiation below that evidence boundary.	Assess renal function and volume first. Same ≥3-day procedure/fasting hold and stable/eating restart rule; evaluate ketoacidosis regardless of glucose.

Finerenone HF potassium algorithm

LVEF ≥40% · act on current dose

Current K⁺	Dose action	Restart / renal qualifier
<5.0 mmol/L	Advance 10→20 mg; at 20 mg, maintain if initial eGFR <60, otherwise advance to 40 mg; maintain 40 mg.	If eGFR has fallen >30% from the prior value, maintain rather than increase.
5.0 to <5.5	Maintain current dose.	Recheck based on trajectory and interacting medicines.
5.5 to <6.0	At 40 mg: reduce to 20 mg. At 20 mg: reduce to 10 mg. At 10 mg: withhold.	After a 10-mg hold, restart 10 mg when K⁺ <5.5.
≥6.0	Withhold at any dose and manage promptly through the urgent hyperkalemia assessment.	Restart 10 mg when K⁺ <5.5; if repeated measurements remain ≥5.5, wait until K⁺ <5.0.

Medication-list triggers that change the plan

interaction screen before each titration

Trigger	Risk	Pharmacist action
TMP-SMX · K⁺ · salt substitute · NSAID	Hyperkalemia, AKI, sodium/fluid retention; may erase RAASi/MRA/diuretic benefit.	Remove/substitute when feasible; repeat K⁺/SCr promptly if exposure is necessary.
Clarithromycin · itraconazole/ketoconazole · ritonavir/cobicistat	Strong CYP3A inhibition can markedly raise eplerenone/finerenone exposure.	Do not coadminister with eplerenone or finerenone; choose an alternative and document the interaction.
Diltiazem · verapamil · fluconazole	Moderate CYP3A effect plus rate slowing; non-DHP CCBs can worsen HFrEF.	Verify indication; apply the eplerenone cap/finerenone K⁺ surveillance and reassess BB/ivabradine bradycardia risk.
Loop diuretic · poor intake · insulin reduction	Volume depletion with SGLT2i; large insulin reduction/fasting increases ketoacidosis risk.	Correct volume depletion, individualize loop change, avoid reflex insulin withdrawal, and give explicit ketone/illness instructions.

Build the agent-specific recheck clock

book it before the patient leaves

Change	First planned check	What closes the loop
ARNI / ARB	BP/orthostasis and K⁺/SCr in about 1–2 weeks; sooner for low BP, CKD, frailty, volume loss, or interacting drugs.	Result reviewed by a named clinician; symptoms and home BP support the next dose, a slower step, or correction of a reversible limiter.
Eplerenone / spironolactone	K⁺/SCr in 3–7 days, again near 4 weeks, after every dose/clinical change, then periodically; intensify for CKD or K⁺-raising exposure.	Act on the trend—not an isolated value—and remove contributors before permanently abandoning a prognostic pillar.
Finerenone	K⁺/eGFR at 4 weeks after initiation, restart, or dose increase, then periodically and after relevant interaction/illness.	Apply the labeled K⁺ algorithm above and document the next test when maintaining, reducing, withholding, or restarting.
SGLT2 inhibitor	No titration. Arrange an early volume/renal touchpoint—often 1–2 weeks when older, CKD, low BP, on a loop, or recently congested.	Weight/volume, intake, symptoms, renal trend when indicated, genital/urinary symptoms, and a clear sick-day/procedure restart owner.
Beta-blocker	HR/rhythm, BP/orthostasis, weight, fatigue, and congestion in about 2 weeks before the next increase.	Advance toward the trial dose only if rhythm, perfusion, and volume permit; do not chase dose through bradycardia or recurrent congestion.

RESTART

A temporary hold is not a discontinuation plan. Record the reason, last dose, required lab or clinical milestone, restart dose, responsible reviewer, and deadline. Never abruptly stop an established beta-blocker without a clinical reason; pregnancy, angioedema, ketoacidosis, severe hyperkalemia, or true hemodynamic instability requires direct prescriber/HF-team management.

These therapies buy different, complementary benefits. In HFrEF, completing all four foundational classes usually creates more value than maximizing one drug while leaving a class absent. The trial effects below compare randomized groups on each study’s background therapy; they are not individualized promises. Populations, controls, follow-up, and adverse-event definitions differ, so rates from different trials should not be compared head-to-head.

HFrEF: the four benefits to explain

prognosis + function + congestion

ARNI · sacubitril/valsartanSURVIVAL + HF ADMISSIONS

Primary: 21.8% vs 26.5% over median 27 mo · HR 0.80

PARADIGM-HF also found all-cause death ↓16%, first HF hospitalization ↓21%, and less symptom/physical limitation burden.

Clinical value: prognostic RAAS/neprilysin therapy with remodeling and natriuretic-peptide effects; it is more than a BP drug.

AE rates · ARNI vs enalapril: symptomatic hypotension 14.0% vs 9.2%; creatinine ≥2.5 mg/dL 3.3% vs 4.5%; cough 11.3% vs 14.3%.

Say: “This helps you live longer and lowers the chance that heart failure puts you in the hospital.” Limiter: usually the strongest BP-lowering pillar.

Evidence-based beta-blockerSUDDEN DEATH + REMODELING

All-cause death: 7.2% vs 11.0% over mean 1 yr · ↓34%

MERIT-HF found sudden death ↓41% and death from worsening HF ↓49%. In severe HFrEF, carvedilol reduced death/CV hospitalization by 27%.

Clinical value: blunts harmful adrenergic drive, stabilizes rhythm, and supports reverse remodeling; benefit develops over weeks to months.

Withdrawal-causing AE · metoprolol vs placebo: bradycardia 0.8% vs 0.2%; hypotension 0.6% vs 0.2%; withdrawal for any AE 9.8% vs 11.7%.

Say: “This protects against dangerous rhythms and helps the heart recover.” Titrate by HR/rhythm; transient fatigue is not proof of no benefit.

MRA · eplerenone/spironolactoneSURVIVAL + CONGESTION

RALES death: 35% vs 46% over mean 24 mo · ↓30%

Symptoms and worsening-HF admission also improved with spironolactone. In milder HFrEF, EMPHASIS-HF CV death/HF hospitalization was 18.3% vs 25.9% over median 21 months (HR 0.63).

Clinical value: blocks aldosterone-driven sodium retention and fibrosis with little BP effect; often helps preserve a four-pillar regimen when BP is tight.

AE rates: EMPHASIS-HF eplerenone vs placebo—K⁺ >5.5 11.8% vs 7.2%; AE discontinuation 13.8% vs 16.2%. RALES male gynecomastia/breast pain, spironolactone vs placebo: 10% vs 1%.

Say: “This blocks a hormone that makes the heart scar and retain salt.” Favor eplerenone when endocrine adverse effects are a concern; monitor K⁺/kidney function.

SGLT2 inhibitor · dapa/empaEARLY HF + KIDNEY BENEFIT

Primary: 16.3% vs 21.2% over median 18.2 mo · HR 0.74

Worsening-HF events fell 30%; CV death fell 18%; benefit was present with or without diabetes. Empagliflozin provides a concordant HFrEF class effect.

Clinical value: early HF-event reduction, kidney/volume support, once-daily dosing, and no titration; reassess whether the loop remains necessary.

Selected AE · dapagliflozin vs placebo: volume depletion 7.5% vs 6.8%; renal AE 6.5% vs 7.2%; AE discontinuation 4.7% vs 4.9%; definite/probable DKA 0.1% vs 0.

Say: “This protects the heart and kidneys and lowers HF visits—even without diabetes.” Jardiance and Farxiga are clinical peers.

Higher EF: name the benefit accurately

fewer HF events ≠ proven mortality benefit

Therapy / phenotype	What the trial showed	What to tell the patient and team
SGLT2i · LVEF >40%	DELIVER primary outcome HR 0.82, driven by worsening HF (HR 0.79); CV death was not significantly lower. Empagliflozin showed a concordant HF-event benefit.	Benefit is mainly fewer worsening-HF events, plus symptom and kidney/volume advantages—not a proven mortality claim. Benefit does not require diabetes.
Finerenone · LVEF ≥40%	FINEARTS-HF reduced total worsening-HF/CV-death events by 16% (RR 0.84), driven by worsening-HF events; CV death was not significantly lower. Investigator-reported hyperkalemia was 9.7% vs 4.2%; worsening-renal-function AEs 18% vs 12%.	Benefit is fewer recurrent/worsening HF events. Prefer when K⁺/eGFR/access allow. TOPCAT directly tested spironolactone; eplerenone lacks equivalent HFpEF outcome evidence. Use only one MRA.
Beta-blocker · HFpEF	No established HFpEF-specific prognostic indication.	Avoid solely for HFpEF. Use for AF/rate control, ischemia, prior MI, or another independent indication; excess rate slowing may worsen exercise tolerance.

Symptom drug versus prognosis drug

do not call them all “BP pills” or “diuretics”

Drug	Primary benefit	Boundary / outpatient use
Loop diuretic	Fastest congestion and symptom relief	No proven survival benefit. Once euvolemic and MRA/SGLT2i are established, taper toward the lowest effective dose or off with a rescue plan.
Ivabradine	Fewer HF admissions; SHIFT primary HR 0.82, driven mainly by HF hospitalization (HR 0.74).	Sinus HFrEF with HR ≥70 despite carvedilol 50 mg BID or metoprolol XL 200 mg daily / maximally tolerated evidence-based BB; not a BB substitute.
Vericiguat	Modest post-worsening-HF event reduction; primary HR 0.90, without significant CV-death reduction.	Possible after recent worsening HFrEF, but lower priority than completing foundational therapy; limited quality-of-life signal.
ARB / ACEi fallback	Retains RAAS prognostic therapy when ARNI is not feasible	Use ARNI when feasible, otherwise ACEi or ARB according to indication and tolerance. Do not overlap. Observe the ACEi washout before ARNI.

PURPOSE

Match the explanation to the drug: ARNI = survival/admission; BB = sudden-death protection/remodeling; MRA = aldosterone/fibrosis/congestion; SGLT2i = HF events/heart-kidney-volume; loop = symptom rescue. A patient who understands the distinct purpose is less likely to stop “duplicate BP pills.”

Do not “start and hope.” A prescription without a lab date, tolerance check, and next titration date is unfinished outpatient care. Reassess stable ambulatory HFrEF about every 1–2 weeks while adding/titrating therapy; recent ED care or HF hospitalization warrants earlier contact and a tighter initial schedule.

A practical optimization cadence

adapt to risk and the agreed care plan

Today · baseline

Reconcile; cause/EF/QRS; BP/HR/weight/volume; K⁺/SCr/eGFR; BNP or NT-proBNP. Start missing classes; book labs/contact.

3–7 days

Risk-based lab check after MRA/RAASi for prior AKI/hyperK, frailty, CKD, major diuretic change, poor intake, or recent acute care.

1–2 weeks

Symptoms, orthostasis, HR/rhythm, weight/volume, adherence/access, K⁺/SCr. Add a class or increase a dose if stable.

Weeks 2–12

Repeat visits, calls, or portal contacts until all four classes are present and doses reach target or a documented maximum tolerated level.

Maintenance

Check BNP/NT-proBNP regularly and with meaningful status change; repeat safety labs after illness, volume change, interaction, or intolerance.

Two standing goals. (1) Natriuretic peptides: trend the same assay with symptoms, exam, weight, and renal function; recognize that NT-proBNP is less directly affected by ARNI. Check often enough to see trajectory, but do not dose to a biomarker target alone—GUIDE-IT did not improve outcomes with that strategy. (2) Loop diuretic: after euvolemia and MRA/SGLT2i implementation, taper stepwise toward the lowest effective dose or off; never taper through residual congestion.

The contact dashboard

same data every time

Domain	Ask / measure	Translate into action
Symptoms / function	Dyspnea, orthopnea/PND, edema, bendopnea, dizziness/syncope, fatigue, exercise tolerance, NYHA class	New congestion or low-output symptoms are not a routine titration visit; route to clinical assessment.
Home data	Daily weights/trend, BP with technique and symptoms, HR/rhythm alerts; verify device and cuff size	Use trends, not one number. Repeat orthostatic vitals when dizziness or falls are present.
Volume / perfusion	Diuretic response, edema, JVP if trained, urine output, thirst/poor intake, coolness/confusion	Distinguish congestion-driven renal change from overdiuresis. If euvolemic, document the next loop reduction/off-trial and rescue trigger.
Medication use	Exact dose/time; missed doses; last fill; tablet splitting; side effects; OTCs/supplements; sick-day holds	Fix the barrier. Prefer a whole-tablet plan the patient will actually take tomorrow.
Labs + peptides	K⁺, SCr/eGFR, Na⁺, Mg²⁺ plus same-assay BNP/NT-proBNP trajectory; align with volume/illness changes	Trend + clinical context determine action. Assign who reviews the result and who calls the patient.
Access	Copay, PA, supply on hand, refill timing, delivery/transport, pharmacy alignment, caregiver support	Do not count a pillar as “started” until the patient can obtain and correctly take it.

Interpret the common limiting signals

avoid reflex discontinuation

Signal	Usually acceptable / first response	Escalate or modify
K⁺ < 5.0	Eligible for MRA if eGFR >30; review supplement/salt-substitute use.	Recheck on schedule after start/dose change.
K⁺ 5.0–5.5	Repeat/confirm; remove K⁺/NSAIDs; review diet, acidosis, constipation, AKI, and interacting drugs.	Individualize RAASi/MRA change with prescriber; increase surveillance. A binder can support continued therapy in selected patients.
K⁺ > 5.5	Do not ignore or wait for a routine visit; assess symptoms, renal trajectory, hemolysis, and ECG need.	Prompt prescriber/urgent hyperkalemia assessment; MRA reduction/hold is usually required if K⁺ cannot be maintained below 5.5.
SCr rise / eGFR dip	A modest early hemodynamic change can occur. Reassess volume, BP, NSAIDs, infection, intake, and diuretic intensity.	Progressive or roughly ≥30% creatinine rise, oliguria, hypotension, or electrolyte change requires prompt clinical review.
Low BP	Asymptomatic low BP alone is not automatic failure. Repeat correctly; check orthostasis/volume; remove non-HF BP drugs and excess loop first.	ARNI is usually the strongest BP lever; downshift/stagger it before abandoning MRA/SGLT2i. Symptoms, syncope, or hypoperfusion → route.
Low HR	BB is an HR/rhythm intervention. Confirm rhythm and remove nonessential rate-slowers before sacrificing evidence-based BB.	Symptoms, HR <50, or new/high-grade block → prescriber/ECG review before the next BB dose change.

Make the decision explicit

green · amber · red

GO Stable, tolerating, labs acceptable.
Start a missing class or increase toward target; give exact instructions; place labs; set the next review date.

PAUSE One correctable constraint.
Fix volume, interacting drug, adherence, cost, timing, or lab issue; preserve other pillars; define the reassessment trigger/date.

ROUTE Clinical instability or safety signal.
No protocol titration. Contact prescriber/HF team now; direct emergency evaluation when severe.

End-of-visit read-back: “Starting tomorrow you will take ___ at ___. Hold/seek help if ___. Your lab is on ___; ___ owns the result. We will contact you on ___ for the next change.” Document the maximally tolerated reason only after the correctable constraints have been addressed.

Use this lane after a recent HF hospitalization—once stable and decongested; this is not a shock pathway. STRONG-HF tested rapid titration of RAS inhibitor/ARNI + BB + MRA across the EF spectrum after an acute-HF admission. High-intensity care reduced 180-day death/HF readmission from 23.3% to 15.2% (RR 0.66) with more nonserious adverse events but no excess serious or fatal events. For a never-hospitalized outpatient, use the urgency and monitoring architecture—not the trial entry criteria—as an operational model.

Five rapid-GDMT principles

Greene · Butler · Fonarow

1 · Reverse the paradox

Higher-risk patients often receive less therapy. Risk is the reason to build a monitored pathway, not to accept inertia.

2 · Speed matters

Benefits emerge within days to weeks. Start pillars simultaneously or in rapid sequence; do not maximize serially.

3 · Start before discharge

The hospital-to-clinic handoff is an implementation opportunity. Leave with medications, labs, and visits already booked.

4 · Measure safety

Rapid care is not unmonitored care. Use repeated vitals, congestion assessment, K⁺/eGFR, and NT-proBNP.

5 · Count omission risk

Weigh the known risk of delaying or omitting proven therapy alongside the potential adverse effect of starting it.

These principles favor complete early coverage plus active surveillance; they do not require forcing an unsafe dose.

The STRONG-HF clock

50% before discharge · 100% by week 2

Time point	Required assessment	Dose action
Entry · ≤2 days before discharge	Clinical stability and improving congestion; all prior-24-h SBP ≥100, HR ≥60, K⁺ ≤5.0; NT-proBNP decreased >10% from screening	Aim for ≥50% of optimal dose of RASi/ARNI, BB, and MRA when eligible; changes may occur the same day or across the final 2 days.
Week 1 · safety	Symptoms/NYHA, full HF exam, BP/HR/weight/congestion; K⁺, kidney function, Na⁺, and NT-proBNP; adherence/access	Confirm tolerance and apply the gates below. If a change is delayed, define the correction and add a safety visit 1 week later.
Week 2 · optimize	Repeat the complete safety dataset before changing therapy	Aim for 100% guideline target or the documented maximum tolerated dose. In the secondary analysis, >90% reached at least medium (≥50%) dosing by week 2; higher achieved doses tracked with better outcomes.
Week 3 · safety	Repeat exam, vitals, congestion, K⁺/kidney function/Na⁺, NT-proBNP, adverse effects and medication use	Maintain safe full doses; restart or advance any temporarily delayed class when the limiting signal resolves.
Week 6 · consolidate	Same dataset plus functional status, access/refills, and the residual loop-diuretic requirement	Close remaining gaps; document target vs maximum tolerated dose, the reason for every ceiling, and the maintenance owner.

Protocol safety gates

pause one move · preserve the rest

Gate	Do not advance when	Immediate response
RASi / ARNI and MRA	SBP <95 mmHg, K⁺ >5.0 mmol/L, or eGFR <30 mL/min/1.73 m²	Hold that titration step; correct volume/interactions, repeat the measurement, and keep unaffected pillars whenever safe.
Beta-blocker	SBP <95 mmHg or HR <55 bpm; also do not increase BB with an early NT-proBNP rise	Reassess rhythm, perfusion and congestion. Remember: BB is the HR/rhythm lever and should not be increased through active congestion.
NT-proBNP rise	>10% above the pre-discharge/randomization value	Delay further titration 1 week; do not increase BB. Reassess for congestion and increase diuretic if clinically congested; repeat the full safety dataset.
Clinical deterioration	New/worsening congestion, symptomatic hypotension/bradycardia, hypoperfusion, AKI, or unsafe electrolyte change	Exit protocol titration; route to same-day HF/prescriber assessment or emergency care when severe.

Translate the trial into this practice

outpatient pharmacist handoff

Contemporary HFrEF	Physiology	Congestion	Execution
STRONG-HF did not protocol-titrate SGLT2i. Add dapagliflozin/empagliflozin early when eligible; no dose titration.	ARNI is usually the BP lever; BB is the HR/rhythm lever. Preserve MRA/SGLT2i when BP is the isolated constraint.	Do not increase BB through congestion. After euvolemia on MRA/SGLT2i, taper the loop toward the lowest effective dose/off.	Every visit ends with the exact change, same-day orders, lab date, next visit, patient teach-back, and one named result owner.

LIMIT

Do not copy the EF-agnostic trial drug list into HFpEF. In contemporary HFpEF, prioritize SGLT2i and finerenone; do not use or up-titrate a BB solely for HFpEF. Pair this page with the drug doses on P.2 and the outpatient dashboard on P.5.

Protect the four classes whenever safely possible. Most “intolerance” is a solvable problem in volume, timing, interacting medications, laboratory surveillance, or patient access. Correct the mechanism; then re-challenge or re-titrate.

Constraint → pharmacist response

mechanism before deletion

Problem	Check first	Preserve benefit / practical move
Symptomatic low BP	Orthostatics; congestion vs dry; diarrhea/poor intake; alpha-blocker, nitrate, CCB, other vasodilator; excessive loop dose	Remove non-HF BP drugs; if euvolemic, trim loop. ARNI is usually the strongest BP lever; stagger/downshift it while preserving MRA/SGLT2i.
Bradycardia / fatigue	ECG/rhythm; digoxin, amiodarone, diltiazem/verapamil; hypothyroidism; sleep apnea; volume/perfusion	BB titration is HR-directed. Remove nonessential rate-slowers first; reduce BB only for symptoms/unsafe rhythm. Avoid BB solely for HFpEF.
Creatinine rise	Congestion, diuretic response, BP, poor intake, infection, NSAID, contrast, urinary obstruction, SGLT2i timing	Treat the cause. Do not equate every stable early eGFR dip with kidney injury; progressive rise, oliguria, hypotension, or electrolyte change needs prompt review.
Hyperkalemia	Repeat nonhemolyzed sample; K⁺ supplement/salt substitute; NSAID; TMP-SMX; AKI; diet; constipation/acidosis	Remove contributors, optimize diuretic if congested, adjust MRA/RAASi with close labs; selected patients may use patiromer/SZC to maintain therapy.
Congestion / weight gain	Adherence, sodium load, NSAID/steroid/TZD, renal change, arrhythmia, ischemia, infection; loop timing/bioavailability	Decongest first; do not increase BB during active congestion. Once euvolemic on MRA/SGLT2i, taper the loop toward lowest effective dose/off.
RAAS intolerance	Cough vs pulmonary congestion; true angioedema; volume/BP; ACEi-to-ARNI timing	Use ARNI when feasible. Otherwise choose ACEi or ARB by indication and tolerance. Angioedema → emergency assessment and permanent culprit-class documentation.
MRA endocrine AE	Gynecomastia, breast pain, sexual dysfunction; dose and renal function	Consider eplerenone for endocrine tolerability when cost/access permit. If on spironolactone, switch within class rather than drop the MRA.
SGLT2i symptoms	Genital infection, volume depletion, poor intake, surgery, insulin reduction, nausea/abdominal pain/dyspnea	Treat uncomplicated genital infection without automatic permanent discontinuation. Suspected euglycemic DKA → stop, check ketones/anion gap, urgent evaluation.

After core GDMT: let mechanism choose escalation

HR · trajectory · etiology · device

Pattern	Trigger	Practice move
Persistent sinus tachycardia	LVEF ≤35% and resting HR ≥70 despite target/max-tolerated evidence-based BB	Verify sinus rhythm, adherence, thyroid/anemia/infection/volume drivers, and a true BB ceiling; then use the ivabradine pathway on P.8.
Recent worsening HFrEF	HF hospitalization or IV diuretic despite the four pillars	Reassess congestion, adherence, ischemia/rhythm, iron deficiency, device candidacy, and advanced-HF trajectory; P.8 lists lower-priority pharmacologic add-ons.
LBBB / dyssynchrony CM	Wide LBBB/QRS with persistently low EF despite GDMT	Medication response may be limited because the mechanism is electrical. Do not keep turning medication knobs while delaying CRT/device evaluation when criteria are met.
Tachyarrhythmia-induced CM	AF/flutter/SVT, mean HR >100, or high ectopy burden plausibly driving EF	Often has the greatest recovery potential: prioritize rhythm/rate or burden control while maintaining GDMT; confirm recovery on follow-up imaging.
Ischemic / scar CM	Prior MI, obstructive CAD, scar pattern, regional dysfunction	EF is often more fixed than tachyarrhythmia CM. Ensure the ischemia/revascularization, ICD/CRT, and secondary-prevention pathways are addressed; do not promise normalization from dose escalation alone.

Etiology changes expectations—not commitment to therapy. Continue HFrEF GDMT after EF improvement; TRED-HF showed frequent relapse after withdrawal.

Medication reconciliation: challenge these

remove the counter-therapy

Medication / product	Why it matters in HF	Pharmacy action
NSAIDs · incl. OTC	Fluid/sodium retention, BP rise, kidney injury, hyperkalemia; can blunt diuretic/RAASi effect.	Stop/avoid when possible; recommend an indication-appropriate alternative and document counseling.
Thiazolidinediones	Fluid retention; may precipitate/worsen symptomatic HF.	Route to diabetes/prescriber team for an alternative.
Diltiazem / verapamil in HFrEF	Negative inotropy; no HFrEF outcome benefit.	Verify indication; do not stop abruptly if used for rate control, but route for a safer strategy.
K⁺ supplement / salt substitute	Raises hyperkalemia risk with ARNI/ACEi/ARB/MRA.	Keep only with a clear indication and monitoring plan; ask specifically about “low-sodium” salt.
OTC decongestant / stimulant	May raise BP/HR or trigger arrhythmia.	Check labels and suggest a symptom-specific alternative; reinforce when to seek care.

URGENT

Same-day HF/prescriber review: new congestion, symptomatic hypotension/bradycardia, rapidly rising K⁺/SCr, or inability to obtain essential therapy. Emergency evaluation: syncope, severe dyspnea, chest pain, confusion/hypoperfusion, angioedema, or suspected ketoacidosis.

These are selected add-ons—not substitutes for incomplete foundational GDMT. Confirm phenotype, rhythm, congestion, adherence, access, and device/etiology needs first. Except for protocolized collaborative-practice use, route initiation through the HF/prescribing clinician.

Selected pharmacologic add-ons

eligibility · dose · benefit · harm

Option	Who / dose	What it buys	Key risk / action
Hydralazine / isosorbide dinitrate	Self-identified Black patients with NYHA III–IV HFrEF on optimal therapy: fixed 20/37.5 mg TID→40/75 mg TID. Also specialist-consider if ARNI/ARB/ACEi cannot be used; evidence is weaker for that route.	A-HeFT, add-on vs placebo: death 6.2% vs 10.2%; first HF hospitalization 16.4% vs 24.4% at mean 12 months.	Headache 47.5% vs 19.2%; dizziness 29.3% vs 12.3%. TID burden, BP, lupus-like syndrome; nitrates + PDE5 inhibitor are contraindicated.
Ivabradine	Stable symptomatic HFrEF, LVEF ≤35%, sinus rhythm HR ≥70 after maximally tolerated evidence-based BB. 5 mg BID with food (2.5 mg if conduction/brady risk) → HR 50–60; max 7.5 mg BID.	SHIFT: CV death/HF admission 24% vs 29% over median 22.9 months, driven mainly by HF admission—not a mortality claim.	Symptomatic bradycardia 5% vs 1%; phosphenes 3% vs 1%. Monitor AF/rhythm; avoid strong/moderate CYP3A inhibitors and pacemaker dependence.
Vericiguat	Symptomatic chronic HF, EF <45%, after HF hospitalization or outpatient IV diuretic. Current label: 5 mg qd with food→10 mg, doubling about every 2 weeks; use 2.5 mg start if symptomatic-hypotension risk.	VICTORIA: CV death/first HF hospitalization 35.5% vs 38.5% over median 10.8 months (HR 0.90); CV death not significantly lower and no meaningful KCCQ advantage.	Consider after foundational therapy. Hypotension 16% vs 15%; anemia 10% vs 7%. Pregnancy contraindicated; no other sGC stimulator; PDE5 inhibitor not recommended.
Digoxin	Selected symptomatic HFrEF despite GDMT or when GDMT is limited. Usually 0.125 mg qd or less in older/CKD patients; individualize to serum 0.5–<0.9 ng/mL.	DIG: HF hospitalization 26.8% vs 34.7% over mean 37 months; mortality neutral (34.8% vs 35.1%).	Suspected-toxicity hospitalization 2.0% vs 0.9%. Renal dosing; K⁺/Mg²⁺, level timing, brady/AV block, nausea/confusion/vision; many P-gp/rate-slowing interactions.

Monitoring bundle for add-ons

eligibility first · owner always

Option	Before the order	Booked follow-up
Hydralazine / ISDN	Seated/standing BP, nitrate/PDE5-inhibitor interaction, headache/dizziness history, and ability to execute TID dosing.	BP, orthostasis, headache, dizziness, adherence, and symptoms; investigate fever, arthralgia, or other lupus-like features.
Ivabradine	Document sinus rhythm, resting HR ≥70, LVEF ≤35%, maximally tolerated evidence-based BB, ECG/conduction status, and CYP3A interactions.	HR/rhythm and tolerance after about 2 weeks; adjust toward HR 50–60 and assess bradycardia, AF, and luminous visual symptoms.
Vericiguat	Recent worsening-HF event, BP/symptoms, hemoglobin/anemia context, interacting sGC/PDE5 therapy, and pregnancy status when relevant.	BP, symptoms, and anemia surveillance with each approximately 2-week dose step; confirm food administration and adherence.
Digoxin	eGFR, K⁺, Mg²⁺, rhythm/conduction, age/weight, and P-gp or rate-slowing interactions; choose a renal-appropriate dose.	Renal/electrolyte trend and a correctly timed level after steady state, dose/interaction change, renal change, or suspected toxicity—not as an isolated number.
IV iron	CBC, ferritin, TSAT, cause of deficiency, blood-loss risk, prior infusion reaction, and product-specific eligibility.	Product-specific infusion surveillance and a defined repletion/iron-index reassessment; continue investigation of the cause.

Hold and route—do not simply delete

name the suspected mechanism

Option	Signal and immediate pharmacist response
Hydralazine / ISDN	Syncope/symptomatic hypotension, a nitrate–PDE5 interaction, or fever/arthralgia/serositis/rash suggesting a lupus-like syndrome → hold the suspected drug when clinically appropriate and contact the prescriber urgently; document any interaction exposure.
Ivabradine	Resting HR <50 with symptoms, new AF, high-grade conduction disease, or uncertainty about pacemaker dependence → ECG/rhythm review and prescriber contact before the next dose or titration.
Vericiguat	Symptomatic hypotension, suspected pregnancy, concurrent sGC stimulator, or worsening anemia symptoms → pause escalation and route promptly; do not use dose escalation to compensate for unresolved congestion.
Digoxin	New bradycardia/AV block/arrhythmia, nausea/vomiting, confusion, color/visual change, acute renal decline, or low K⁺/Mg²⁺ → hold and obtain a clinical assessment with ECG, chemistry, renal function, and a correctly timed level.

SELECT

Sequence: complete/preserve the four pillars → correct congestion, interactions, adherence, and access → confirm the add-on eligibility → pair the order with its monitoring owner. Vericiguat and digoxin are not routine “fifth pillars,” and none of these options replaces a needed rhythm, device, or advanced-HF referral.

Persistent symptoms or a stagnant EF are not automatically a request for another drug. Recheck congestion and foundational GDMT, then identify iron deficiency, rhythm burden, ischemic scar, and electrical dyssynchrony. This is a stable-outpatient guide, but advanced-HF referral should occur before shock or irreversible end-organ dysfunction.

Iron deficiency is a treatable HF comorbidity

ferritin + TSAT · not hemoglobin alone

Screen and define

Order CBC, ferritin, and transferrin saturation (TSAT); iron deficiency = ferritin <100 ng/mL, or ferritin 100–300 with TSAT <20%.
Look for blood loss, nutritional/GI cause, CKD, inflammation, and antithrombotic contribution; treat the cause as well as repletion.
Oral iron did not improve exercise capacity in HFrEF; guideline-supported HF treatment uses intravenous iron in appropriate iron-deficient HFrEF.

Set the expectation

Primary goals: improve functional status, symptoms, and quality of life; selected trials suggest fewer HF admissions. Do not promise mortality benefit.
AFFIRM-AHF after stabilization from acute HF: total HF hospitalizations RR 0.74; CV death 14% vs 14%. The recurrent HF-hospitalization/CV-death endpoint narrowly missed significance.
Coordinate product-specific dosing and infusion/adverse-effect surveillance; book CBC, ferritin, and TSAT reassessment and continue the cause evaluation.

When more medication is not the answer

define the recovery mechanism

Pattern	Do now	Practice lens
LBBB / wide QRS + low EF	Confirm QRS morphology/duration, rhythm, pacing burden, EF trajectory, symptoms, and GDMT duration; route for CRT/device evaluation when criteria may be met.	Dyssynchrony cardiomyopathy may respond incompletely to drug escalation; do not delay a mechanism-matched therapy.
Potential tachyarrhythmia CM	Quantify AF/flutter/SVT or ectopy burden; prioritize rhythm/rate/burden control with EP/cardiology while preserving tolerated GDMT.	Recovery potential is often greater than in fixed ischemic/scar cardiomyopathy; reassess EF after the culprit is controlled.
Ischemic / scar phenotype	Clarify coronary anatomy, prior infarct/revascularization, ischemic symptoms, and relevant imaging; manage ischemia and secondary prevention with cardiology.	Scar burden may constrain EF recovery. Set realistic goals while preserving the event and symptom benefits of GDMT.
Advanced-HF trajectory	Recurrent HF care, escalating loop need, hyponatremia, end-organ decline, low BP limiting therapy, cachexia, inotrope need, or intolerance of multiple pillars → advanced-HF review.	Referral while ambulatory preserves options; do not wait for shock, irreversible organ dysfunction, or repeated crisis care.

Send a decision-ready referral

reduce rework · preserve options

Referral	Include in the handoff
Device / CRT	12-lead ECG with QRS morphology/duration; rhythm and pacing burden; current/prior LVEF with dates; NYHA symptoms; GDMT agents, doses, duration, and objective limiters; relevant coronary history.
EP / arrhythmia-CM	ECGs and ambulatory-monitor burden/rates; timing versus EF decline; prior rhythm/rate therapy and response; K⁺/Mg²⁺/TSH; symptoms/syncope; anticoagulation status when AF/flutter is present.
Advanced HF	HF ED/hospital/IV-diuretic events; loop-dose trajectory; BP and GDMT intolerance; Na⁺, renal/liver trend, NT-proBNP; weight/cachexia; functional decline; right-sided symptoms; goals, support, and major comorbidities.
Iron / cause workup	CBC indices, ferritin, TSAT and dates; bleeding/GI/renal context; antithrombotics; prior oral/IV iron and reactions; selected formulation and ownership of post-repletion testing.

Choose the escalation lane

stable referral ≠ urgent deterioration

Lane	Examples	Action
Planned specialty review	Persistent low EF with LBBB/wide QRS; measured arrhythmia burden; iron deficiency; uncertain recovery mechanism; stable advanced-HF risk signal.	Place the decision-ready referral, complete prerequisite testing, and assign the follow-through milestone.
Same-day HF / prescriber	Rapidly rising weight or loop need, new/worsening congestion, symptomatic hypotension/bradycardia, syncope/presyncope, rapidly changing K⁺/SCr/Na⁺, or inability to obtain essential therapy.	Stop protocol titration; contact the responsible clinician now for examination, testing, and disposition.
Emergency evaluation	Severe resting dyspnea/hypoxia, chest pain/possible ACS, syncope with instability, confusion/hypoperfusion, angioedema, or suspected ketoacidosis.	Use the emergency response system; do not manage by portal message or a routine future appointment.

Close the mechanism loop

a referral is not the endpoint

EF milestone	Rhythm milestone	Referral milestone	Iron milestone
Repeat imaging date and the decision it will trigger are documented.	Burden is measured; control strategy and post-control reassessment are assigned.	Order accepted, urgency clear, appointment/owner known, and required testing completed.	Repletion completed; cause addressed; CBC/ferritin/TSAT recheck booked and reviewed.

REFER

Do not let “optimize GDMT” become an indefinite holding pattern. Preserve tolerated pillars while the mechanism is evaluated, and document the EF/rhythm/lab milestone that will trigger the next decision. Escalate new instability through the urgent clinical assessment rather than routine titration.

Adherence is a clinical problem to diagnose, not a character judgment. In one HF RCT, a pharmacist intervention improved adherence by 10.9 percentage points and reduced ED visits/hospitalizations by 19.4%; the effect waned after the intervention stopped. A newer multicenter RCT improved 52-week proportion of days covered by 8.1% with longitudinal pharmacist-led management. The implication: one-time education is not a system.

Ask → listen → fix the exact barrier

nonjudgmental · specific · closed loop

Barrier	Useful question	Practical fix
Cost / coverage	“What did the pharmacy say the price would be? Which prescription did you leave behind?”	Real-time formulary check; generic/covered alternative; PA; copay/PAP; 30- vs 90-day math; confirm pickup/delivery and next refill.
Complexity / routine	“Walk me through yesterday from waking to bedtime. Which pills are you cutting or skipping?”	Prefer whole-tablet strengths; do not build the plan around half tablets unless the patient accepts and can do it. Align timing; synchronize fills; pillbox/blister pack; written purpose map.
Side effect / fear	“Which symptom worries you, and what happened after which pill?”	Name likely culprit; validate; explain benefit/time course; adjust timing/dose or switch within class; give a rescue/escalation plan; re-challenge deliberately.
Belief / no symptoms	“What do you think these medicines are doing for you?”	Link each drug to the patient’s goal: stay home, breathe/walk farther, protect kidney/heart, be present for family. Explain prevention despite feeling well.
Literacy / cognition	“How confident are you that you could show someone else exactly how to take these?”	Plain language, large-print visual schedule, teach-back, interpreter, caregiver, pharmacy packaging; remove contradictory lists.
System / access	“What usually prevents the refill or follow-up from happening?”	Delivery/transport, automatic refill, lab location/hours, portal/phone route, caregiver authorization, single accountable pharmacy/HF contact.

Teach-back: the five things the patient must be able to do

ask for a demonstration, not “do you understand?”

Name the schedule: point to each whole tablet, dose, time, and purpose; demonstrate any unavoidable split.
Recognize fluid change: daily weight/edema/dyspnea plan; know whom to call and when.
Use hold rules: explain the specific SGLT2i/illness/procedure plan and restart trigger.
Find the feedback loop: state the lab date, next visit/contact, and owner of results.
Show access: medication in hand or confirmed fill/delivery; correct pharmacy and refill plan.

Suggested close: “I want to make sure I explained this clearly. Show me how you will take these tomorrow, and what you will do if you are sick or the pharmacy price is too high.” Teach-back improved HF self-care and self-efficacy in a randomized discharge study.

One-sentence purpose map

ARNI	“Relaxes the circulation and changes the heart’s stress signals to help you live longer and stay out of the hospital.”
Beta-blocker	“Protects the heart from excess stress and helps it work more efficiently over time.”
MRA	“Blocks a hormone that drives salt retention and heart scarring; it also helps the congestion plan.”
SGLT2i	“Protects the heart and kidneys, lowers HF events, and may reduce the fluid-pill requirement—even without diabetes.”
Loop diuretic	“Relieves extra fluid and symptoms; our goal is the lowest dose you need, sometimes none.”

Access: make “started” mean obtained

verify before the patient leaves

Coverage formulary tier, PA/step criteria, quantity limits, mail-order requirement, deductible phase.
Lowest safe path generic/covered equivalent, 90-day fill, copay card when eligible, manufacturer/PAP, cost-plus option.
First fill confirm stock, copay, pickup/delivery, and actual possession; record the next refill date before closing the visit.
Continuity synchronize fills and assign the pharmacy/team that will manage renewal, labs, and titration.

Pharmacy continuity

Assign a pharmacy partner for affordability, prior authorization, refills and longitudinal medication follow-up.
At every visit confirm preferred pharmacy, delivery plan, days of medication on hand, refill due date, and who renews each prescription.
After hospitalization, confirm the discharge supply and transfer refill, safety-lab and titration responsibility to the ambulatory team.

Documentation that another clinician can act on

copy the structure, not the patient data

HF PHENOTYPE: LVEF ___% (date/trajectory ___); HFrEF / HFimpEF / HFmrEF / HFpEF; etiology ___; rhythm/QRS/LBBB ___; NYHA ___; last HF event ___.
STATUS: BP ___/___ (orthostasis ___); HR/rhythm ___; weight trend ___; congestion/perfusion ___; K⁺ ___; SCr/eGFR ___; BNP/NT-proBNP ___ (date/trend ___).
GDMT MAP: ARNI / ARB / ACEi ___; evidence-based BB + HR target ___; MRA ___; SGLT2i ___; loop dose/taper goal ___; missing/subtarget reason(s) ___.
TODAY: start/stop/change ___ to ___ on ___; interacting medication addressed ___; rationale ___.
ADHERENCE / ACCESS: barrier(s) ___; whole-tablet plan ___; fix ___; fill/cost confirmed ___; teach-back demonstrated ___.
FOLLOW-UP: labs ___ on ___; result owner ___; patient contact/visit ___; next intended titration ___; escalation instructions ___; prescriber/team notified ___.

DONE

A pharmacist encounter is complete only when the patient has an obtainable regimen, understands the plan, knows the hold/escalation rules, and has a booked feedback loop. Work within the collaborative practice agreement and the agreed care plans; verify all doses, renal thresholds, formulary rules, and urgent-care pathways.